Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Bioregenx (BRGX) Receivables - Net (2023 - 2025)

Bioregenx has reported Receivables - Net over the past 3 years, most recently at $39718.0 for Q4 2025.

  • For Q4 2025, Receivables - Net rose 164.93% year-over-year to $39718.0; the TTM value through Dec 2025 reached $39718.0, up 164.93%, while the annual FY2025 figure was $39718.0, 164.93% up from the prior year.
  • Receivables - Net for Q4 2025 was $39718.0 at Bioregenx, down from $62610.0 in the prior quarter.
  • Over five years, Receivables - Net peaked at $104581.0 in Q4 2023 and troughed at $10943.0 in Q2 2024.
  • A 3-year average of $32859.0 and a median of $19442.0 in 2024 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: plummeted 85.66% in 2024 and later surged 222.03% in 2025.
  • Year by year, Receivables - Net stood at $104581.0 in 2023, then plummeted by 85.66% to $14992.0 in 2024, then surged by 164.93% to $39718.0 in 2025.
  • Business Quant data shows Receivables - Net for BRGX at $39718.0 in Q4 2025, $62610.0 in Q3 2025, and $21115.0 in Q2 2025.